Posted by Michael Wonder on 25 Feb 2017
Revlimid (lenalidomide) approved by the European Commission as monotherapy for the maintenance treatment of patients with newly diagnosed multiple myeloma after autologous stem cell transplantation
24 February 2017 - The new indication expands the availability of Revlimid across the disease continuum of multiple myeloma.
Celgene today announced that the European Commission has approved Revlimid (lenalidomide) as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Revlimid is the first and only licensed maintenance treatment available to these patients.
The Revlimid marketing authorisation has been updated to include this new indication, which expands on the existing multiple myeloma indications as combination therapy for the treatment of those not eligible for transplant who are newly diagnosed, or have received at least one prior therapy.
